Edgewise Therapeutics (EWTX) Net Cash Flow (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Net Cash Flow data on file, last reported at -$27.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 438.43% year-over-year to -$27.9 million; the trailing twelve-month figure through Mar 2026 stood at -$16.7 million (down 185.01% YoY), and the FY2025 full-year result was $19.5 million, up 143.85% from the prior year.
• Net Cash Flow fell to -$27.9 million in Q1 2026, from $15.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $91.4 million in Q3 2022 to a low of -$87.8 million in Q4 2022.
• A 5-year average of $1.0 million and a median of $1.3 million in 2024 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow plunged 1856.84% in 2022 and soared 582.32% in 2025, its largest moves.
• Tracing EWTX's Net Cash Flow over 5 years: stood at -$87.8 million in 2022, then soared by 160.56% to $53.1 million in 2023, then sank by 105.91% to -$3.1 million in 2024, then soared by 582.32% to $15.1 million in 2025, then tumbled by 284.46% to -$27.9 million in 2026.
• Business Quant data shows EWTX's Net Cash Flow at -$27.9 million in Q1 2026, $15.1 million in Q4 2025, and $2.6 million in Q3 2025.